UPDATE: Clovis Oncology (CLVS) Misses Q1 EPS by 4c (Correction)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts CLVS Hot Sheet
Join SI Premium – FREE
(Updated - May 6, 2015 3:57 PM EDT)
Clovis Oncology (NASDAQ: CLVS) reported Q1 EPS of ($1.86), $0.04 worse than the analyst estimate of ($1.82). Revenue for the quarter came in at $0 , versus $13.6 million reported last year.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Eli Lilly & Co. (LLY) Tops Q3 EPS by $1.88, Beats on Revenue; Offers FY26 Guidance
- Brunswick (BC) Tops Q3 EPS by 22c, Misses on Revenue; Offers Guidance
- CRH plc (CRH) Tops Q3 EPS by 6c, cuts forecast
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
